Zeniya M: Thyroid disease in autoimmune liver diseases. Ghilardi G, Gonvers JJ, So A: Hypothyroid myopathy as a complication of interferon alpha therapy for chronic hepatitis C virus infection. : Autoimmune hepatitis associated with thyroiditis and hypophysitis. : Autoimmune hemolytic anemia in chronic hepatitis C virus infectioin treated with alpha-interferon: A therapy-related event or extra-hepatic immunologic manifestation?. Giannoccaro F, Pace L, Antonaci S, et al. Huang MJ, Liaw YF: Clinical associations between thyroid and liver diseases. : Early-onset autoimmune hepatitis is associated with a C4A gene deletion. Aust NZ J Med 3:124–128, 1973įarrell GC: Drug-Induced Liver Disease. Stuttgart: FK Schattauer-Verlag, 1975 pp 319–325Ĭooksley WGE, Cowen AE, Powell LW: The incidence of oxyphenisatin ingestion in active chronic hepatitis: A prospective controlled study of 29 patients. Reynolds TB, Peters RL, Yamada S: Chronic active and lupoid hepatitis caused by a laxative, oxyphenisatin. : Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy. : Development of arthritis and hypothyroidism during alpha-interferon therapy for chronic hepatitis C. : Autoimmune hepatitis induced by alpha-interferon therapy in a patient with chronic myeloid leukemia. Digestion 22:66–72, 1981Īl-Ashgar H, Al-Sohaibani F, Kagevi I, et al. : Chronic active hepatitis and giant multinucleated hepatocytes in adults treated with clometacin. A model of drug-induced autoimmune hepatitis?. : Drug-induced hepatitis with autoimmune features during minocycline therapy. Arch Pediatr Adolesc Med 152:1132–1136, 1998Ībe M, Furukawa S, Takayama S, et al.
#Hidata disease series
: Minocycline-related autoimmune hepatitis: Case series and literature review. Teitelbaum JE, Perez-Atayde AR, Cohen M, et al. : Minocycline as a cause of drug-induced autoimmune hepatitis: Report of four cases and comparison with autoimmune hepatitis. Goldstein NS, Bayati N, Silverman AL, et al. : Minocycline-induced hepatitis with autoimmune features and neutropenia. Am J Gastroenterol 92:143–146, 1997īhat G, Jordan J Jr, Sokalski S, et al. Goldstein PE, Devier J, Cremer M: Acute hepatitis and drug-related lupus induced by minocycline treatment. : Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. : Hepatic injury associated with the use of nitrofurans: A clinical pathological study of 52 cases. Stricker BHCH, Blok APR, Claas FHJ, et al. Iwarson S, Lindberg J, Lunden P: Nitrofurantoin induced chronic liver disease: clinical course and outcome of five cases. A report of a patient with HLA-B8 antigen. : Nitrofurantoin: Another cause of drug-induced chronic active hepatitis?. Hatoff DE, Cohen M, Schweigart DF, et al. Lundgren R, Back O, Wiman LG: Pulmonary lesions and autoimmune reactions after long term nitrofurantoin treatment. Selroos O, Edgren J: Lupus-like syndrome associated with pulmonary reaction to nitrofurantoin: Report of three cases. Sharp JR, Ishak KG, Zimmerman HJ: Chronic active hepatitis and severe hepatitis necrosis associated with nitrofurantoin. Am J Med 60:941–948, 1976Īrranto AJ, Sotaniemi WEA: Morphologic alteration in patients with α-methyldopa-induced liver damage after short and long term exposure. Rodman JS, Deutsch DJ, Gutman SI: Methyldopa hepatitis: A report of six cases and review of the literature. Goldstein GB, Lam KC, Mistilis SP: Drug-induced chronic hepatitis. New York, Elsevier Science BV, 1998, pp 627–649 Lewis J, Zimmerman H: Drug-induced autoimmune liver disease. MMWR Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for the treatment of latent infection-United States, 2003, Morb Mortal Wkly Rep, 52, 735–739, 2003 : Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: A multicenter clinical trial. Jasmer RM, Saukkonen JJ, Blumberg HM, et al. CMAJ 169:937–938, 2003įatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection-New York and Georgia, 2000. Weir E, Fisman DN: Latent tuberculosis: revised treatment guidelines.
0 kommentar(er)
